Evidence map›Paper›PMID 40171464›Full record

ReviewEcancermedicalscience2024

Current landscape of BRAF-V600E metastatic CRC management in Latin America: an expert Latin American panel's recommendations.

Anelisa K Coutinho, Yazmin Carolina Blanco Vazquez, Markus Andret Cavalcante Gifoni, Angela Marie Jansen, Juan Manuel O'Connor, Juan Carlos Samamé Pérez-Vargas, Mariana Rico-Restrepo, Gayatri Sanku, Guillermo Mendez

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Ecancermedicalscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anelisa K CoutinhoClínica AMO, DASA, Salvador, Bahia, Brazil.
Yazmin Carolina Blanco VazquezCentro Médico ABC Observatorio, Ciudad de Mexico 01120, Mexico.
Markus Andret Cavalcante GifoniUniversidade Federal do Ceara, Fortaleza 60430-160, Brazil.
Angela Marie JansenAmericas Health Foundation, Washington, DC, USA.
Juan Manuel O'ConnorInstituto Alexander Fleming, Buenos Aires, Argentina.
Juan Carlos Samamé Pérez-VargasClínica San Felipe, Lima, Peru.
Mariana Rico-RestrepoAmericas Health Foundation, Bogota, Colombia.
Gayatri SankuAmericas Health Foundation, Washington, DC, USA.
Guillermo MendezHospital de Gastroenterologia 'Carlos Bonorino Udaondo', Buenos Aires 1264, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is the second leading cause of cancer death in Latin America (LA) with a projected 65.4% increase by 2040. Up to 10% of metastatic CRC (mCRC) patients in LA had an activating BRAF mutation. In clinical trials, targeted therapies for BRAF-V600E mutated mCRC have improved patient outcomes. However, in LA, BRAF-V600E testing and treatment of positive patients remains variable. To address this need, the Americas Health Foundation convened a meeting of LA experts on

Indexed as

mCRC in Latin Americametastatic colorectal cancerprecision medicineV600E-BRAF mCRCV600E-BRAF-mutation

Identifiers

PMID40171464
PMCPMC11959131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.